QL1A - QuidelOrtho Corporation (DB) - Share Price and News

QuidelOrtho Corporation
DE ˙ DB ˙ US2197981051
23,80 € ↑0.20 (0.85%)
2025-09-04
SHARE PRICE
Overview
QuidelOrtho Corporation is a leading entity in the healthcare industry, primarily focusing on diagnostics healthcare solutions. Based in the United States, the corporation delivers a comprehensive range of products and technologies that are central to diagnostic testing for infectious diseases, cardiometabolic issues, and toxicology. Among its key projects, QuidelOrtho excels in rapid point-of-care testing kits and robust laboratory equipment, which are pivotal in advancing global health standards. The company, through its innovative pursuits, has positioned itself at the forefront of addressing crucial health challenges, implementing streamlined diagnostics that significantly enhance patient care and clinical outcomes. QuidelOrtho's enduring commitment to innovation and accessibility in diagnostic healthcare continues to drive its strategic operations and market expansion.
Basic Stats

The share price of QuidelOrtho Corporation as of 4 September 2025 is 23,80 € / share. This is a decrease of -1.65% from the prior week. The market cap (or net worth) of QuidelOrtho Corporation as of 5 September 2025 is 1.611,26 € MM.

The Factor Analysis chart (below right) shows a view of QuidelOrtho Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.

For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.

Market Cap 1,611.26 MM
EV
Shares Out. 67.70 MM
Earnings Date
EPS (TTM) -6.89
Dividend Yield
Ex-Dividend Date
Borrow Rate 0.49
Short Shares Avail. 0.00 MM
Short Interest
Short Float
Days to Cover
Risk Free Rate 4.17 %
Price Change (1 yr) -39.90 %
Volatility (1 yr) 0.63
Beta 1.49
Sharpe Ratio (1 yr) -0.70
Sortino Ratio (1 yr) -1.30
PE Ratio
Price/Book
Price/TBV
Book/Market
EBIT/EV
EBIT(3yr avg)/EV
ROA -0.07
ROE -0.15
ROIC -0.08
CROIC 0.01
OCROIC 0.04
Implied Volatility
Put/Call OI Ratio
Growth 20.28 /100
Profitability 38.85 /100
Quality Score 39.83 /100
Value Score
Momentum Score 36.18 /100
Stability (Low Vol) Score 26.38 /100
Analyst Sentiment
Fund Sentiment 35.31 /100
Insider Sentiment
Officer Sentiment
Dividend Score
QVM Score
Piotroski F-SCORE
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for QuidelOrtho Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Date Analyst Prior Latest
Recommendation
Action
No data available.
Other Listings
MX:QDEL1
GB:0A55
US:QDEL 28,68 US$
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista